New hope for melanoma patients who Don't respond to standard immunotherapy
NCT ID NCT06999980
First seen Nov 19, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests new combinations of immunotherapy drugs given before surgery to people with advanced melanoma that can be removed. The goal is to see if these combinations can reduce or eliminate the tumor before surgery, lowering the chance the cancer comes back. The trial is for patients whose melanoma is expected to respond poorly to standard immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.